MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1878313

Maia Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyMaia Biotechnology, INC. (MAIA)
Form Type8-K
Filed DateSep 10, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Disclosure

TL;DR

MAIA Bio filed an 8-K on Sept 10th, check it for updates.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on September 10, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific details regarding the nature of these events or any associated financial figures were not immediately available in the provided text.

Why It Matters

This filing indicates that MAIA Biotechnology, Inc. is providing updates to the SEC, which could contain material information for investors regarding the company's operations or financial status.

Risk Assessment

Risk Level: medium — The filing of an 8-K often signifies important company events, but the lack of specific details in the provided text necessitates a medium risk assessment until the content is fully analyzed.

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The provided text does not specify the exact nature of the Regulation FD Disclosure.

What are the 'Other Events' reported by MAIA Biotechnology, Inc.?

The filing mentions 'Other Events' but does not detail what these events are in the provided text.

Are there any significant financial statements or exhibits included with this 8-K filing?

The filing indicates 'Financial Statements and Exhibits' are included, but their content is not detailed in the provided text.

When was MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. was incorporated in Delaware.

What is the principal executive office address for MAIA Biotechnology, Inc.?

The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Filing Stats: 1,146 words · 5 min read · ~4 pages · Grade level 13.7 · Accepted 2024-09-10 06:15:29

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 10, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing